
Figure 1 of 26



BEST AVAILABLE COPY

Figure 2 of 26




Figure 3 of 26

Oligosaccharide	2/m	m/z MRM	P2 fraction	GAG
		pair		
IdoA- GalNAc4SQ-UA-GalNAo UA (+SQ)	027	720/269	#31 and #32	DS
IdoA- GalNAc4SQ-UA- GalNAc (+SQ)	632	632/298	#34 and #35	DS
IdoA- GalNAc4SQ-UA	382	697/786	#38 and #39	DS
	490	490/173		
IdoA-HN-UA (+SQ.)	940	940/269	#37	HS
IdoA-HN-UA (+2SQ)	1020	1020/940	#37	HS
	509	509/422		
IdoA- HNAc (+SQ)	908	806/295	#40 and #41	HS/DS


^a IdoA, iduronic acid; GalNAc, Nacetylgalactosamine; GalNAc4SON acetylgalactosamine

^{4 -} sulfate; UA, uronic acid; HN, hexosamine; HNAc, Nacetylhexosamine.

^b fractions from the Bio- Gel P2 column (see Figure 23).

proposed source of oligosaccharide (DS, dermatan sulfate; HS, heparan sulfate).

Figure 4 of 26






Figure 5 of 26






Figure 6 of 26



2

Figure 7 of 26



8/26

Figure 8 of 26

Relative oligosaccharide levels in controla urine

Oligosaccharide	Q1/Q3°	Average value ^d	Std. Dev.
UA	523/173	0.1480	0.1119
HNAc	550/173	0.0036	0.0028
HNAcS	630/256	0.0016	0.0007
HNAcS2	710/256	0.0030	0.0018
HNAc-UA	726/331	0.0155	0.0196
(HINAG. UA)	726/173	0.0063	0.0072
(HNS, UA)	764/173	0.0736	0.0295
HNS-UA	764/331	0.1148	0.1041
(HNAc. UA. S)	806/173	0.0003	
UA-HNAcS	806/295	0.1941	0.1198
HNAcs-UA	806/331	0.0999	0.0882
UA-HN-UA (S)	940/269	0.0294	0.0106
UA-HNAc-UA (S)	982/286	0.0111	0.0120
UA-HNAc-UA (S)	490/173	0.0045	0.0029
UA-HNAc-UA (S)	490/476	0.0305	
UA-HN-UA (S2)	1020/269	0.0026	
UA-HN-UA (S2)	1020/940	0.0018	0.0015
UA-HN-UA (S2)	509/422	0.0011	0.0018
HNAc-UA-HNAc (S2)	544/173	0.0507	
HNAc-UA-HNAc-UA (S)	1185/931	0.0099	
HNAc-UA-HNAc-UA (S)	591/173	0.2024	0.1818
HNAc-UA-HNAc-UA (S2)	632/298	0.0556	
UA-HNAc-UA-HNAc-UA (S2)	720/269	0.0024	0.0024
HNAc-UA-HNAc-UA-HNAc	734/173	0.0044	0.0027
HNAc-UA-HNAc-UA-HNAc (S3)	515/173	0.0291	
Unknown	528/448	0.0195	
Hexasaccharide	764/256	0.0007	0.0006

 $^{\rm a}$ Controls = 26

b UA=uronic acid, HN=hexosamine, HNAc=N-acetylhexosamine, S=sulphate, structures

in brackets indicate unknown sequence. c m/z values used for the MRM analysis of selected oligosaccharides.

^d values refer to the ratio values of the oligosaccharide signals to the internal standards GlcNAc6S (d3) (used for the monosaccharides) and the chondroitin disaccharide α - Δ UA-[1-3]-GalNAc-6S (used for disaccharides and larger species).

Mann Whitney U values for oligosaccharide analytes in MPS subgroups^d compared to controls^e

	MPST	MPS II	MPS IIIA	MPS IIIA MPS IIIB MPS IIIC MPS IIID	MPS IIIC		MPS IVA MPS VI	MPS VI	MS
Olimearcharidea	15	13	12	7	77		9	10	1
On Bosecular rec									
114	184	156.5	136	75	19.5°	24.5	20	æ	7
AND	128	123.5	g	26	40	56	53	106	2
FINAC TRIA -S	7 P	101	47.9	£ 5	27	0	۹ 0	0 و	5.5
HINACS	0 y	127	ş Ç	×	; 2 ²	4	30°	7 p	4
HINACS2	200	134.5	117	43 م	8	21	51	55 p	က
HINAC-UA	5.7	123	, ye	3 F	23.5	10	36	62°	5
(HINAC, UA)	2 4	4 P	3.5	49.5	25	, , , ,	32€	104	0
HNS 114	114 5°	17 ^b	င်	51	44.5	1^{c}	42	75.5	0
TING TIA CO	150	71.5 b	81.5	26 ^b	20	9	54	98	5
(HIVAC, OA, 3)	Q O	q O	120.5	8	45	5°	<i>L</i> 9	115	00
HNA 25-17A	194	152	154	9/	38	0 0	1 p	4	m
IIA_HN_IIA (S)	15.5 ^b	140	139.5	91	35.5	6	63	11	0
_	9 0	53 _b	146	88	35	21	70.5	8	7
	75.5 b	153	140	65	45	5	38	108	7
11A-HNAC-11A (S)	o	2	140	51	36	23	67.5	128	'n
-	169	52 ^b	_q 99	40 و	7 p	21	37°	48բ	6
11A_HN_11A (S2)	86.5 ^b	134	113.5	81	48	22	71	115	1
11A_HN_11A (S2)	24 b	136	q 69	9/	46	22	75	%	0
HNA C. 11A. HNA C (\$2)	109	78 p	133.5	78	46	10	15.5 ^b	ر و2 و	2
HNAC-IIA-HNAC-IIA (S)	q ₀	134	64 p	0 0	22	3°	10^{b}	29 _p	0
	61 b	89	128	34°	37	11	2 6	118.5	13
HNAC-11A-HNAC-11A (S2)	, c	130	31 b	S _b	78	0°	10.5 ^b	0	0
IIA-HNAC-IIA-HNAC-IIA (S2)	61.5 ^b	131	101.5	71.5	31	∞	29	122.5	7
HNAC-11A-HNAC-11A-HNAC	188	76.5 ^b	°06	63	27	17	20	108	4
HNAc-11A-HNAc-11A-HNAc (S3)	167	55.5 ^b	125	44.5°	20	17	89	105	=
Inknown (528/448)	60.5 ^b	54 _b	43 b	57	24	8.5	41	110 -	7
Hexasaccharide (764/256)	q 0	9 0	13 b	1 p	3 _p	0°	2 ₀	a S	0
TANAMAMATAN (C.) TIME L	LINIAGE	Vocatalha	Vocamine	-enluhate c	tructures in	brackets inc	licate unkno	mown sequence	શું

Figure 9 of 26

UA=uronic acid, HN=hexosamine, HNAc=N-acetylhexosamine, S=sulphate, structures in brackets indicate unknown sequence.
 b p<0.01
 c p<0.5
 d MPS types are shown with the number of patient samples below

Figure 10 of 26






Figure 11 of 26



12/26

Figure 12 of 26






Figure 13 of 26

Cell line	Disorder	$UA-HN-UA(Sx2)^{1}$
or 3344	Control	0.034
SF 5248	Control	0.030
SF 2662	MPS I (intermediate)	0.000
SF 5048	MPS I (severe)	0.379
SF 538	MPS I (severe)	0.387
¹ relative level	1 relative level of oligosaccharide/mg cell protein	otein
UA = uronic a	UA = uronic acid; HN = hexosamine	

Figure 14 of 26

Genotype	632/298	982/269	940/269	1020/269	509/422	806/295
	(MRM)	(MRM)	(MRM)	(MRM)	(MRM)	(MRM)
W402Xhom	30.8	93.6	14.0	4.8	20.0	111.8
W402X, Q70X	5.4	10.9	1.0	3.3	1.0	51.4
W180X, c134-145del	5.6	5.7	0.55	69.0	1.6	25.2
P533R, W402X	4.4	5.7	0.67	0.32	1.1	40.9
R89Q, 1060+2t>c	3.4	2.7	0.13	0.33	0.89	11.3
R89Q, 1060+2t>c	5.4	2.2	0.19	0.19	1.0	10.5
L346R, c704ins5	2.7	1.5	0.21	0.18	99.0	9.1
Control range (n=26)	0.07-0.9	0.07-0.9 0.07-0.6 0.02-0.2	0.02-0.2	0-4.0	9.0-0	0.03-0.5

Figure 15 of 26

Oligosaccharide ¹ MRM	1 MRM	Pre-BMT	Pre-BMT Post-BMT Post-BMT Control	Post-BMT		Control
ı	pairs		(3 months)	(3 months) (8 months) Avg (n=8)	_	Std Dev
UA-HN-UA(Sx2) 509/422) 509/422	2.31	0.63	0.59	0.05	0.03
HNAc(S)	630/256	192	165	139	89	52
UA-HINAc(S)	806/295	13.93	8.39	2.12	0.04	0.02
UA-HN-UA(S)	940/269	0.49	0.21	0.19	0.03	0.02
UA-HINAc-	982/269	2.58	1.86	1.05	90.0	0.04
UA(S)						
UA-HNAc-UA- 632/298 9.34	632/298	9.34	4.51	2.57	0.23	0.16
HINAc(Sx2)						
1 UA = uronic acid; HN = hexosamine; S = sulphate; HNAc = N-acetylhexosamine	id; HN = h	exosamine;	S = sulphate	HNAc = N	l-acetylhexo	samine

Figure 16 of 26




Figure 17 of 26




Figure 18 of 26




Figure 19 of 26

19/26




Figure 20 of 26




Figure 21 of 26




Figure 22 of 26




Figure 23 of 26





Figure 24 of 26






Figure 25 of 26





Figure 26 of 26



This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.